9 results on '"Scrobohaci, Marie-Lorraine"'
Number of results to display per page
Search Results
2. [Recommendations for venous thromboembolic events treatment and central venous catheter thrombosis management in cancer patients]
- Author
-
Elias, Antoine, Debourdeau, Philippe, Renaudin, Jean Marc, Desmurs-Clavel, Hélène, Mahé, Isabelle, Elalamy, Ismail, Pavic, Michel, Kassab-Chahmi, Diana, Bosquet, Lise, Cajfinger, Francis, Desruennes, Eric, Douard, Marie-Cécile, Grange, Claire, Hocini, Hamid, Kriegel, Irène, Le Gal, Grégoire, Meyer, Guy, Mismetti, Patrick, Quéré, Isabelle, Scrobohaci, Marie-Lorraine, Lévesque, Hervé, Farge-Bancel, Dominique, Institut de Physique du Globe de Paris (IPGP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Génomique, développement et pouvoir pathogène (GD2P), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA), Service de Médecine Interne, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Signalisation cellulaire, dynamique circulatoire et athérosclérose précoce (SCDCAP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Roland Mousnier Histoire et Civilisation (CRM), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris-Sorbonne (UP4)-Centre National de la Recherche Scientifique (CNRS), Immunopathologie humaine, Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Ecole Vétérinaire de Toulouse, Groupe de recherche sur la thrombose (GRT (EA 3065)), Université Jean Monnet [Saint-Étienne] (UJM), Service de Médecine Interne [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Hôpital Lariboisière, Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), École pratique des hautes études (EPHE)-Université Paris-Sorbonne (UP4)-Centre National de la Recherche Scientifique (CNRS), Université de Brest (UBO), Service de Médecine Interne [Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Institut de Physique du Globe de Paris ( IPGP ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -IPG PARIS-Université Paris Diderot - Paris 7 ( UPD7 ) -Université de la Réunion ( UR ) -Centre National de la Recherche Scientifique ( CNRS ), Génomique, développement et pouvoir pathogène ( GD2P ), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique ( INRA ), Signalisation cellulaire, dynamique circulatoire et athérosclérose précoce ( SCDCAP ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de Recherche Roland Mousnier Histoire et Civilisation ( CRM ), École pratique des hautes études ( EPHE ) -Université Paris-Sorbonne ( UP4 ) -Centre National de la Recherche Scientifique ( CNRS ), Institut National de la Santé et de la Recherche Médicale ( INSERM ), Groupe d'Etude de la Thrombose de Bretagne Occidentale ( GETBO ), Université de Brest ( UBO ), Groupe de recherche sur la thrombose ( GRT (EA 3065) ), Université Jean Monnet [Saint-Étienne] ( UJM ), CHU Rouen-Université de Rouen Normandie ( UNIROUEN ), and Normandie Université ( NU ) -Normandie Université ( NU )
- Subjects
Catheterization, Central Venous ,MESH : Venous Thromboembolism ,MESH: Clinical Trials as Topic ,MESH: Societies, Medical ,MESH: Academies and Institutes ,MESH : Treatment Outcome ,MESH : Randomized Controlled Trials as Topic ,Catheterization ,MESH: Venous Thromboembolism ,Central Venous ,Neoplasms ,Medical ,MESH : Societies, Medical ,Humans ,MESH: Neoplasms ,MESH: Thrombosis ,MESH : France ,Societies, Medical ,Randomized Controlled Trials as Topic ,MESH: Treatment Outcome ,Clinical Trials as Topic ,MESH: Catheterization, Central Venous ,MESH: Humans ,MESH : Humans ,Academies and Institutes ,[ SDV.SP.PHARMA ] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Thrombosis ,Venous Thromboembolism ,MESH : Neoplasms ,MESH : Thrombosis ,MESH : Clinical Trials as Topic ,MESH: France ,Treatment Outcome ,MESH: Randomized Controlled Trials as Topic ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,France ,MESH : Academies and Institutes ,Societies ,MESH : Catheterization, Central Venous - Abstract
International audience; The "Standards, Options: Recommendations" (SOR) project has been undertaken by the French National Federation of Cancer Centers (FNCLCC) and is now part of the French National Cancer Institute. The project involves the development and updating of evidence-based Clinical Practice Guidelines (CPG) in oncology. In order to answer questions related to venous thromboembolic events (VTE) treatment and to central venous catheter thrombosis (CVCT) management in cancer patients, the SOR elaborated national guidelines, here presented in a short report. It results of a collaborative work with members from three learned societies (<< Société nationale française de médecine interne >> : SNFMI, << Société française de médecine vasculaire >> : SFMV and << Société française d'anesthésie-réanimation >> : SFAR).
- Published
- 2009
- Full Text
- View/download PDF
3. [2008 Standards, Options: Recommendations for venous thromboembolic events(VTE)treatment and central venous catheter thrombosis(CVCT) management in cancer patients]
- Author
-
Renseigné, Non, Mahé, Isabelle, Elalamy, Ismail, Farge-Bancel, Dominique, Mismetti, Patrick, Scrobohaci, Marie-Lorraine, Hocini, Hamid, Meyer, Guy, Kassab-Chahmi, Diana, Bosquet, Lise, Cajfinger, Francis, Desmurs-Clavel, Hélène, Desruennes, Eric, Douard, Marie-Cécile, Elias, Antoine, Grange, Claire, Kriegel, Irène, Le Gal, Grégoire, Lévesque, Hervé, Pavic, Michel, Renaudin, Jean Marc, Quéré, Isabelle, Debourdeau, Philippe, Service de Médecine Interne, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Signalisation cellulaire, dynamique circulatoire et athérosclérose précoce (SCDCAP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Groupe de recherche sur la thrombose (GRT (EA 3065)), Université Jean Monnet [Saint-Étienne] (UJM), Immunopathologie humaine, Institut National de la Santé et de la Recherche Médicale (INSERM), Ecole Vétérinaire de Toulouse, Institut de Physique du Globe de Paris (IPGP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Roland Mousnier Histoire et Civilisation (CRM), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris-Sorbonne (UP4)-Centre National de la Recherche Scientifique (CNRS), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Service de Médecine Interne [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Génomique, développement et pouvoir pathogène (GD2P), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA), Hôpital Lariboisière, Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), École pratique des hautes études (EPHE)-Université Paris-Sorbonne (UP4)-Centre National de la Recherche Scientifique (CNRS), Université de Brest (UBO), Service de Médecine Interne [Rouen], Université de Rouen Normandie (UNIROUEN), and Normandie Université (NU)-Normandie Université (NU)-CHU Rouen
- Subjects
Oral ,Infusions ,Catheterization, Central Venous ,Administration, Oral ,MESH: Anticoagulants ,Catheterization ,MESH: Venous Thromboembolism ,Kidney Failure ,Central Venous ,Neoplasms ,Humans ,MESH: Neoplasms ,MESH: Heparin, Low-Molecular-Weight ,Renal Insufficiency ,MESH: Infusions, Intravenous ,Infusions, Intravenous ,MESH: Catheterization, Central Venous ,MESH: Humans ,Heparin ,Low-Molecular-Weight ,Anticoagulants ,Venous Thromboembolism ,Heparin, Low-Molecular-Weight ,MESH: Kidney Failure ,Administration ,MESH: Administration, Oral ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Intravenous - Abstract
International audience; The Standards, Options: Recommendations (SOR) project has been undertaken by the French National Federation of Cancer Centers (FNCLCC) is now part of the French National Cancer Institute. The project involves the development and updating of evidence-based Clinical Practice Guidelines (CPG) in oncology. In order to answer questions related to venous thromboembolic events(VTE) treatment and to central venous catheter thrombosis (CVCT) management in cancer patients, the SOR elaborated national guidelines, here presented in a short report. It results of a collaborative work with members from three learned societies("société nationale française de médicine interne": SNFMI, "société française de médicine vasculaire": SFMV and "société française dEanesthésie-réanimation:SFAR).
- Published
- 2008
- Full Text
- View/download PDF
4. [2008 Standards, Options: recommendations for venous thromboembolic events (VTE) treatment and central venous catheter thrombosis (CVCT) management in cancer patients]
- Author
-
Debourdeau, Philippe, Farge-Bancel, Dominique, Bosquet, Lise, Kassab-Chahmi, Diana, Cajfinger, Francis, Desmurs-Clavel, Hélène, Desruennes, Eric, Douard, Marie-Cécile, Elias, Antoine, Elalamy, Ismail, Grange, Claire, Hocini, Hamid, Kriegel, Irène, Le Gal, Grégoire, Lévesque, Hervé, Mahé, Isabelle, Meyer, Guy, Mismetti, Patrick, Pavic, Michel, Quéré, Isabelle, Renaudin, Jean Marc, Scrobohaci, Marie-Lorraine, Institut de Physique du Globe de Paris (IPGP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Signalisation cellulaire, dynamique circulatoire et athérosclérose précoce (SCDCAP), Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), Centre de Recherche Roland Mousnier Histoire et Civilisation (CRM), École pratique des hautes études (EPHE)-Université Paris-Sorbonne (UP4)-Centre National de la Recherche Scientifique (CNRS), Immunopathologie humaine, Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Service de Médecine Interne [Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU), Service de Médecine Interne, Hôpital Lariboisière, Ecole Vétérinaire de Toulouse, Groupe de recherche sur la thrombose (GRT (EA 3065)), Université Jean Monnet [Saint-Étienne] (UJM), Génomique, développement et pouvoir pathogène (GD2P), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris-Sorbonne (UP4)-Centre National de la Recherche Scientifique (CNRS), Université de Brest (UBO)-Université de Brest (UBO), Service de Médecine Interne [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Hôpital Lariboisière-Fernand-Widal [APHP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
Oral ,Male ,Vena Cava Filters ,MESH: Heparin ,Hemorrhage ,MESH: Anticoagulants ,MESH: Catheterization ,Catheterization ,MESH: Venous Thromboembolism ,Fibrinolytic Agents ,Recurrence ,Neoplasms ,Thromboembolism ,Humans ,MESH: Fibrinolytic Agents ,MESH: Neoplasms ,MESH: Vena Cava Filters ,Aged ,MESH: Aged ,MESH: Humans ,MESH: Middle Aged ,Heparin ,Anticoagulants ,Venous Thromboembolism ,Middle Aged ,MESH: Male ,MESH: Recurrence ,MESH: France ,MESH: Thromboembolism ,Administration ,MESH: Administration, Oral ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Female ,France ,MESH: Female ,MESH: Hemorrhage - Abstract
TheStandards, Options : Recommendations(SOR) project has been undertaken by the French National Federation of Cancer Centers (FNCLCC) is now part of the French National Cancer Institute. The project involves the development and updating of evidence-based Clinical Practice Guidelines (CPG) in oncology. In order to answer questions related to venous thromboembolic events (VTE) treatment and to central venous catheter thrombosis (CVCT) management in cancer patients, the SOR elaborated national guidelines, here presented in a short report. It results of a collaborative work with members from three learned societies ("société nationale française de médicine interne": SNFMI, "société française de médicine vasculaire": SFMV and "société française d'anesthésie-réanimation": SFAR).
- Published
- 2008
- Full Text
- View/download PDF
5. [Standards, Options: recommendations 2008; thromboembolic events treatment, prophylaxis and treatment of central venous catheter thrombosis in patients with cancer]
- Author
-
Kriegel, Irène, Desruennes, Eric, Douard, Marie-Cécile, Grange, Claire, Renaudin, Jean Marc, Meyer, Guy, Scrobohaci, Marie-Lorraine, Kassab-Chahmi, Diana, Bosquet, Lise, Cajfinger, Francis, Desmurs-Clavel, Hélène, Elias, Antoine, Elalamy, Ismail, Farge-Bancel, Dominique, Hocini, Hamid, Lévesque, Hervé, Mahé, Isabelle, Mismetti, Patrick, Pavic, Michel, Quéré, Isabelle, Le Gal, Grégoire, Debourdeau, Philippe, Centre de Recherche Roland Mousnier Histoire et Civilisation (CRM), École pratique des hautes études (EPHE)-Université Paris-Sorbonne (UP4)-Centre National de la Recherche Scientifique (CNRS), Génomique, développement et pouvoir pathogène (GD2P), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA), Ecole Vétérinaire de Toulouse, Institut de Physique du Globe de Paris (IPGP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Signalisation cellulaire, dynamique circulatoire et athérosclérose précoce (SCDCAP), Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), Immunopathologie humaine, Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Médecine Interne [Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU), Service de Médecine Interne, Hôpital Lariboisière, Groupe de recherche sur la thrombose (GRT (EA 3065)), Université Jean Monnet [Saint-Étienne] (UJM), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris-Sorbonne (UP4)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Service de Médecine Interne [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Université de Brest (UBO)-Université de Brest (UBO)
- Subjects
Catheterization, Central Venous ,MESH: Catheterization, Central Venous ,MESH: Humans ,Thrombosis ,Catheterization ,Central Venous ,MESH: Thromboembolism ,Neoplasms ,Thromboembolism ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Humans ,MESH: Neoplasms ,MESH: Thrombosis ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2008
6. [2008 Standards, Options: Recommendations for venous thromboembolic events(VTE)treatment and central venous catheter thrombosis(CVCT) management in cancer patients].
- Author
-
Mahé I, Elalamy I, Farge-Bancel D, Mismetti P, Scrobohaci ML, Hocini H, Meyer G, Kassab-Chahmi D, Bosquet L, Cajfinger F, Desmurs-Clavel H, Desruennes E, Douard MC, Elias A, Grange C, Kriegel I, Le Gal G, Lévesque H, Pavic M, Renaudin JM, Quéré I, and Debourdeau P
- Subjects
- Administration, Oral, Anticoagulants administration & dosage, Anticoagulants therapeutic use, Catheterization, Central Venous methods, Heparin, Low-Molecular-Weight administration & dosage, Heparin, Low-Molecular-Weight therapeutic use, Humans, Infusions, Intravenous, Renal Insufficiency complications, Venous Thromboembolism drug therapy, Venous Thromboembolism etiology, Catheterization, Central Venous adverse effects, Neoplasms complications, Neoplasms therapy, Venous Thromboembolism therapy
- Abstract
The Standards, Options: Recommendations (SOR) project has been undertaken by the French National Federation of Cancer Centers (FNCLCC) is now part of the French National Cancer Institute. The project involves the development and updating of evidence-based Clinical Practice Guidelines (CPG) in oncology. In order to answer questions related to venous thromboembolic events(VTE) treatment and to central venous catheter thrombosis (CVCT) management in cancer patients, the SOR elaborated national guidelines, here presented in a short report. It results of a collaborative work with members from three learned societies("société nationale française de médicine interne": SNFMI, "société française de médicine vasculaire": SFMV and "société française dEanesthésie-réanimation:SFAR).
- Published
- 2008
- Full Text
- View/download PDF
7. [2008 Standards, Options: recommendations for venous thromboembolic events (VTE) treatment and central venous catheter thrombosis (CVCT) management in cancer patients].
- Author
-
Debourdeau P, Farge-Bancel D, Bosquet L, Kassab-Chahmi D, Cajfinger F, Desmurs-Clavel H, Desruennes E, Douard MC, Elias A, Elalamy I, Grange C, Hocini H, Kriegel I, Le Gal G, Lévesque H, Mahé I, Meyer G, Mismetti P, Pavic M, Quéré I, Renaudin JM, and Scrobohaci ML
- Subjects
- Anticoagulants adverse effects, Anticoagulants therapeutic use, Catheterization adverse effects, Fibrinolytic Agents therapeutic use, France, Heparin adverse effects, Heparin therapeutic use, Humans, Vena Cava Filters, Venous Thromboembolism prevention & control, Neoplasms complications, Venous Thromboembolism therapy
- Abstract
The <
- Published
- 2008
- Full Text
- View/download PDF
8. [Standards, Options: recommendations 2008; thromboembolic events treatment, prophylaxis and treatment of central venous catheter thrombosis in patients with cancer].
- Author
-
Kriegel I, Desruennes E, Douard MC, Grange C, Renaudin JM, Meyer G, Scrobohaci ML, Kassab-Chahmi D, Bosquet L, Cajfinger F, Desmurs-Clavel H, Elias A, Elalamy I, Farge-Bancel D, Hocini H, Lévesque H, Mahé I, Mismetti P, Pavic M, Quéré I, Le Gal G, and Debourdeau P
- Subjects
- Catheterization, Central Venous adverse effects, Humans, Thromboembolism prevention & control, Thromboembolism therapy, Catheterization, Central Venous standards, Neoplasms complications, Thromboembolism etiology, Thrombosis etiology
- Published
- 2008
- Full Text
- View/download PDF
9. [Pathophysiology of thrombotic microangiopathies: current understanding].
- Author
-
Coppo P, Veyradier A, Durey MA, Fremeaux-Bacchi V, Scrobohaci ML, Amesland F, and Bussel A
- Subjects
- ADAM Proteins, ADAMTS13 Protein, Autoimmunity, Complement Factor H deficiency, Hemolytic-Uremic Syndrome etiology, Hemolytic-Uremic Syndrome pathology, Humans, Microcirculation, Platelet Aggregation, Purpura, Thrombotic Thrombocytopenic etiology, Purpura, Thrombotic Thrombocytopenic pathology, Risk Factors, Hemolytic-Uremic Syndrome physiopathology, Metalloendopeptidases deficiency, Purpura, Thrombotic Thrombocytopenic physiopathology, von Willebrand Factor physiology
- Abstract
Thrombotic microangiopathies (TMA) encompass various severe diseases characterized by microangiopathic hemolytic anemia and peripheral thrombocytopenia, associated with fever, neurological signs and renal involvement. Microvascular thrombosis is the typical lesion, and results in tissue ischemia. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are the two most classical forms. These two entities are clinically and histopathologically closely related. There is a body of evidence suggesting that endothelial cell injury is the initial event in TTP and HUS, and that it may be related to a large number of triggering factors, such as infection, connective tissue disease, drugs, cancer and chemotherapy, transplantation, and pregnancy. Endothelial cell injury enhances the release of ultra large forms of von Willebrand factor (ULvWF) multimers and other prothrombotic agents, such as plasminogen activator inhibitor and platelet activating factor, whereas it decreases the release of prostaglandin-I2, a strong inhibitor of platelet aggregation. Recently however, it has been shown that TTP and HUS were pathophysiologically distinct. Actually, TTP is associated with a deficiency in von Willebrand factor-cleaving protease, an enzyme involved in cleavage of ULvWF into circulating 200 kDa and 350 kDa fragments. This deficiency may be either congenital or acquired, and then related to an IgG inhibitory autoantibody. This protease deficiency may account for the high amounts of plasmatic ULvWF in TTP patients. In HUS, vWF-cleaving protease activity is found normal. HUS encompasses two distinct entities. Epidemic, or diarrhea-associated HUS, is associated with verotoxin or Shiga toxin-associated enterobacteriaceae. These toxins are directly responsible for endothelial cell injury. Sporadic HUS (also termed atypical HUS in children) is closely related to TTP, and shares the same triggering factors. Familial HUS has been associated in some cases with hypocomplementemia and factor H dysfunction, the pathophysiological role of which remains unclear. The study of the different triggering factors and predisposing factors may be useful to define different subsets of TMA, that may be characterized by their course and prognosis.
- Published
- 2002
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.